European Pharmaceutical Review
APRIL 10, 2025
In the EU, a joint PFAS Restriction Proposal under REACH was submitted, aiming for a full ban by 2028/2030. This poses a significant challenge for pharmaceutical manufacturers, not least because of the technical challenges related to operations, supply chain and the environment. There is worldwide concern around the use of PFAS.
Express Pharma
NOVEMBER 5, 2024
The global enoxaparin market was valued at US $3,315 million in 2023 and is projected to reach US $5,415 million by 2030, growing at a rate of 7.1 per cent from 2024 to 2030. PIC/S comprises 52 active member states and fosters cooperation between regulatory authorities and the pharmaceutical industry to promote GMP.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JULY 18, 2023
A market report by Meticulous Research has reported that rising pressure to reduce overall process costs has meant many pharma and biotech manufacturers are focusing on streamlining their processes by using quality management systems. According to the research, the pharmaceutical quality management systems market is projected to reach $3.97
Express Pharma
NOVEMBER 13, 2024
Renowned as a comprehensive, one-stop destination for innovative, cost-effective solutions, the expo will be showcasing the pharmaceutical industry’s modernisation, innovation, and sustainability. India’s pharma industry is on an impressive growth trajectory, expected to reach $65 billion by 2024 and to double to $130 billion by 2030.
Express Pharma
JANUARY 17, 2025
We have committed to reduce our scope 1 and 2 GHG emissions by 42 per cent (absolute) by the end of 2030 (from a 2021 basis). To achieve this goal, the company is focusing on transitioning to renewable electricity and carbon-free heat, reducing energy consumption, and redesigning manufacturing processes to reduce energy consumption and waste.
European Pharmaceutical Review
JUNE 10, 2024
The first industrial-scale pharmaceutical manufacturing facility for production of lead-212-based radioligand therapies has been inaugurated. The company hopes to produce this number tenfold by the end of 2030.
European Pharmaceutical Review
OCTOBER 31, 2022
According to the Intergovernmental Panel on Climate Change (IPCC), emissions must achieve reduction of 43 percent by 2030. Sustainable energy strategies for pharmaceutical manufacturers… The post Biopharma successful in achieving climate-related goals, report finds appeared first on European Pharmaceutical Review.
Expert insights. Personalized for you.
59 
Let's personalize your content